<DOC>
	<DOCNO>NCT01499147</DOCNO>
	<brief_summary>New conditioning regimen still need maximize efficacy limit treatment-related death allogeneic transplantation advance hematologic malignancy . Over past several year , investigator evaluate several new condition regimens incorporate fludarabine , novel immunosuppressant limit toxicity synergistic activity alkylating agent . Recent data suggest fludarabine may use combination standard dose oral IV busulfan , thus reduce toxicity previously observe cyclophosphamide/ busulfan regimen .</brief_summary>
	<brief_title>Fludarabine Based Conditioning Allogeneic Transplantation Advanced Hematologic Malignancies</brief_title>
	<detailed_description>Treatment-related mortality recurrence disease account majority treatment failure allogeneic transplantation advance hematologic malignancy . The commonly utilized conditioning regimen consist cyclophosphamide total-body irradiation busulfan cyclophosphamide . Other agent etoposide thiotepa sometimes add maximize antileukemic effect . New condition regimen however still need maximize efficacy limit treatment-related death . Over past several year , investigator evaluate several new condition regimens incorporate fludarabine , novel immunosuppressant limit toxicity synergistic activity alkylating agent . Recent data suggest fludarabine may use combination standard dose oral IV busulfan , thus reduce toxicity previously observe cyclophosphamide/ busulfan regimen .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Vidarabine Phosphate</mesh_term>
	<criteria>Patients follow disease : Acute myeloid lymphocytic leukemia first remission standard highrisk recurrence . Acute leukemia great equal second remission , early relapse , partial remission . Chronic myelogenous leukemia accelerate phase blastcrisis . Chronic myelogenous leukemia chronic phase Recurrent refractory malignant lymphoma Hodgkin 's disease Multiple myeloma . Chronic lymphocytic leukemia , relapse poor prognostic feature . Myeloproliferative disorder ( polycythemia vera , myelofibrosis ) poor prognostic feature . Severe aplastic anemia failure immunosuppressive therapy . Age 1065 year . Zubrod performance status less equal 2 . Adequate cardiac pulmonary function . Patients decrease LVEF &lt; 40 % DLCO &lt; 50 % predict evaluated cardiology pulmonary prior enrollment protocol . Patient guardian able sign inform consent . Life expectancy severely limited concomitant illness . Serum creatinine great 1.5 mg/dL Creatinine Clearance less 50 ml/min . Serum bilirubin great equal 2.0 mg/dl , SGPT great 3 x upper limit normal Evidence chronic active hepatitis cirrhosis HIVpositive Patient pregnant</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>First remission</keyword>
	<keyword>Acute lymphocytic leukemia</keyword>
	<keyword>Acute leukemia</keyword>
	<keyword>Second remission</keyword>
	<keyword>Early relapse</keyword>
	<keyword>Partial remission</keyword>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>Accelerated phase</keyword>
	<keyword>Blast-crisis</keyword>
	<keyword>Chronic phase</keyword>
	<keyword>Recurrent malignant lymphoma</keyword>
	<keyword>Refractory malignant lymphoma</keyword>
	<keyword>Hodgkin 's disease</keyword>
	<keyword>Multiple myeloma .</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Myeloproliferative disorder</keyword>
	<keyword>Polycythemia vera</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Severe aplastic anemia</keyword>
</DOC>